Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Adaptimmune Ther ADR
(NQ:
ADAP
)
1.580
+0.000 (+0.01%)
Streaming Delayed Price
Updated: 1:52 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Adaptimmune Ther ADR
< Previous
1
2
Next >
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
March 27, 2024
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
March 06, 2024
U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date...
Via
Newsfile
Topics
Economy
Exposures
Product Safety
Supply Chain
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
February 27, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
February 21, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
January 31, 2024
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for...
Via
Newsfile
Exposures
Product Safety
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
January 04, 2024
Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be...
Via
Newsfile
Exposures
Product Safety
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
December 06, 2023
First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug AdministrationAfami-cel data demonstrate better...
Via
Newsfile
Exposures
Product Safety
Adaptimmune Receives Transfer of IND for Lete-cel Program
November 29, 2023
Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma...
Via
Newsfile
Adaptimmune Reports Third Quarter Financial Results and Business Update
November 08, 2023
Afami-cel: overall survival for people with synovial sarcoma who received afami-cel is superior to historic controls (CTOS 2023); BLA submission...
Via
Newsfile
Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
November 08, 2023
Candidate is 10x more sensitive to target peptide than competitor candidatesEntry into the clinic in 2024Selection of approaches from next-gen...
Via
Newsfile
Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
October 31, 2023
~39% of patients who received afami-cel in the pivotal SPEARHEAD-1 trial had clinical responses with a median duration of response...
Via
Newsfile
Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
October 31, 2023
40% (18/45) of people with synovial sarcoma or MRCLS and who have received ≥ 2 prior lines of therapy had...
Via
Newsfile
Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
October 25, 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in...
Via
Newsfile
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
October 23, 2023
35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across...
Via
Newsfile
Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
September 11, 2023
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces...
Via
Newsfile
Adaptimmune Reports Second Quarter Financial Results and Business Update
August 09, 2023
Substantial progress on the afami-cel BLA including FDA agreement on plan for confirmatory evidence and favorable feedback on commercial T-cell...
Via
Newsfile
Exposures
Product Safety
Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023
August 03, 2023
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader...
Via
Newsfile
Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
June 01, 2023
First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023Compelling clinical...
Via
Newsfile
Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO
May 25, 2023
Approximately 39% of patients had clinical responses after a single dose of afami-cel in Cohort 1 of the pivotal SPEARHEAD-1...
Via
Newsfile
Adaptimmune Reports First Quarter Financial Results and Business Update
May 12, 2023
Completed submission of the clinical module (Part 2) of the afami-cel BLA; afami-cel is targeted to be the first marketed...
Via
Newsfile
Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023
April 28, 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - April 28, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell...
Via
Newsfile
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
April 11, 2023
- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy -- Adaptimmune and GSK will...
Via
Newsfile
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics Inc. (Nasdaq – TCRR), Costar Technologies, Inc. (OTC –
March 30, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company
March 06, 2023
TCR2 Therapeutics, Inc. (NASDAQ: TCRR) operates as a clinical-stage immunotherapy company, which is focused on the research and development of
Via
Spotlight Growth
ADAP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Adaptimmune Therapeutics plc Is Fair to Shareholders
March 06, 2023
From
Halper Sadeh LLC
Via
Business Wire
Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update
March 06, 2023
BLA submission initiated for afami-cel, with aim to complete in mid-2023; afami-cel has the potential to be the first marketed...
Via
Newsfile
Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
March 06, 2023
Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors...
Via
Newsfile
Adaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023
February 22, 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - February 22, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in...
Via
Newsfile
Adaptimmune Announces Changes to Board of Directors
February 16, 2023
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 16, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in...
Via
Newsfile
Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma
January 09, 2023
-The response rate was 44% in patients with late-stage, metastatic synovial sarcoma after a single dose of afami-cel --...
Via
Newsfile
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.